

# Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis

Information for the public

Published: 3 September 2025

[www.nice.org.uk](http://www.nice.org.uk)

Benralizumab (Fasenra) is available on the NHS as a possible treatment for eosinophilic granulomatosis with polyangiitis that comes back after treatment (is relapsing) or has stopped responding to treatment (is refractory) in adults. Benralizumab would be taken in addition to your usual medication for the condition.

If your condition does not improve enough, your healthcare practitioner will stop your benralizumab after 52 weeks and speak to you about possible next steps.

## Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on shared decision making](#).

## Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

## Information and support

The [NHS webpage on granulomatosis with polyangiitis](#) may be a good place to find out more.

[Vasculitis UK](#) (0300 365 0075) can give you advice and support.

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-7159-6